Atigliflozin
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 647834-15-9
- Formule: C18H22O7S
- Masse moléculaire:382.43
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
hSGLT2 10 nM (IC50) |
hSGLT1 8.2 μM (IC50) |
AVE2268 (10-100 mg/kg, p.o.) dose-dependently decreases blood glucose excursions after glucose (i.p. or p.o.) administration in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 647834-15-9
-
Masse moléculaire 382.43
-
Formule C18H22O7S
-
SMILES
O[C@H]1[C@H](OC2=C(CC3=CC=C(OC)C=C3)SC=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
-
Synonyms
AVE-2268
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Schudok M, et al. The magic of small structure differences in a sodium-glucose cotransporter drug discovery project-14 C-labelled drug candidates in a key-differentiating study. J Labelled Comp Radiopharm. 2021 Feb;64(2):73-76. [Content Brief]
[2]. Bickel M, et al. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)